PR positive breast cancer is a result of immunohistochemistry examination, PR positive breast cancer generally has a better prognosis and can be treated with endocrine therapy. PR is the abbreviation of progesterone receptor, and PR positive breast cancer is a result of immunohistochemistry examination, which indicates that there is progesterone receptor on the surface of the patient’s tumor cells, which will be controlled by progesterone, PR expression >20% generally represents a better prognosis for the patients with modified breast cancer, or else it represents a high risk of recurrence of breast cancer. At this stage, the more commonly used endocrine therapy drug for PR-positive breast cancer is tamoxifen, which needs to be adhered to for 5 years or until the patient develops drug-resistance or intolerable side effects, and the drug should be used in strict accordance with the doctor’s instructions, and regular checkups should be carried out during the treatment period.